Additionally, a subset of pancreatic, mucinous ovarian, colorectal, gastric, adrenocortical, and endometrial cancers harbor loss‐of‐function mutations in E3‐ubiquitin ligases RNF43 or its paralog ZNRF3 or gene fusions leading to activation of Wnt agonists RSPO2/3 (R‐spondin 2/3) (Wu et al, 2011; Bailey et al, 2016; Ryland et al, 2013; Wang et al, 2014; Giannakis et al, 2014; Assié et al, 2014; Seshagiri et al, 2012). The gene discussed is RSPO2; the disease is endometrial cancer.